# Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

> **NCT05215405** · — · NO_LONGER_AVAILABLE · sponsor: **Kathleen Ludwig**

## Conditions studied

- Relapsed Childhood ALL
- Relapsed Childhood Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Navitoclax

## Key facts

- **NCT ID:** NCT05215405
- **Lead sponsor:** Kathleen Ludwig
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05215405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05215405, "Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05215405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*